Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.3SBio and Ascentage Pharma Group (Ascentage Pharma) have formed a strategic alliance to research, develop and commercialise cancer therapeutics focusing on programmed cell death, or apoptosis.
Subscribe to our email newsletter
The alliance is expected to leverage Ascentage’s expertise in structure-based small molecule design, lead optimisation and preclinical development with 3SBio’s proven drug development and commercialisation capabilities in China.
As per the terms of the agreement, 3SBio will make a $3m equity investment in Ascentage to fund its R&D programs. 3SBio will have the exclusive right to develop and commercialise cancer therapeutics in China that are discovered through Ascentage programs, while Ascentage Pharma will retain the rights to the rest of the world and receive future milestone and royalty payments from any sales by 3SBio in China.
Jing Lou, CEO of 3SBio, said: “The collaboration with Ascentage represents a key strategic initiative for 3SBio to develop our pipeline in the area of cancer therapeutics. This investment allows 3SBio to gain access to the best external science and small molecule drug discovery platform in China.”
Dajun Yang, CEO of Ascentage, said: “Apoptosis targeted small molecule has the potential to play a key role in the next generation of highly effective targeted cancer drugs. We believe that this ‘win-win’ collaboration will generate innovative medicines that benefits patients worldwide.”